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Abstract
Cervical cancer is the second most common cancer among women worldwide,
with developing countries accounting for >80% of the disease burden. Although
in the West, active screening has been instrumental in reducing the incidence
of cervical cancer, disease management is hampered due to lack of biomarkers
for disease progression and defined therapeutic targets. Here we carried out
gene expression profiling of 29 cervical cancer tissues from Indian women,
spanning International Federation of Gynaecology and Obstetrics (FIGO) stages
of the disease from early lesion (IA and IIA) to progressive stages (IIB and
IIIA–B), and identified distinct gene expression signatures. Overall, metabolic
pathways, pathways in cancer and signaling pathways were found to be signifi-
cantly upregulated, while focal adhesion, cytokine–cytokine receptor interaction
and WNT signaling were downregulated. Additionally, we identified candidate
biomarkers of disease progression such as SPP1, proliferating cell nuclear
antigen (PCNA), STK17A, and DUSP1 among others that were validated by
quantitative real-time polymerase chain reaction (qRT-PCR) in the samples
used for microarray studies as well in an independent set of 34 additional
samples. Integrative analysis of our results with other cervical cancer profiling
studies could facilitate the development of multiplex diagnostic markers of
cervical cancer progression.
Introduction
Cervical carcinoma is the second most common cancer
affecting women worldwide (age-standardized rate, world,
ASR [W], of 15.2), accounting for more than half a mil-
lion new cases every year [1]. From a study in India, the
three most common fatal cancers reported in women at
30–69 years of age were cervical (33,400 [17.1%]), stom-
ach (27,500 [14.1%]), and breast (19,900 [10.2%]) [2].
Persistent infection by high-risk human papillomavirus
(HPV) is the central etiological factor for the develop-
ment of cervical cancer [3]. Although early detection and
advancement in diagnostic and treatment modalities have
led to improved disease management and increased
survival of patients in developed countries, in India cervi-
cal carcinoma still continues to be the most common
cancer among women and accounts for the maximum
cancer deaths each year. Majority of cervical carcinoma
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are curable if diagnosed at an early stage. Despite this, it
causes as many deaths as breast cancer which has an inci-
dence rate nearly double that of cervical cancer [1]. A
major reason behind this disparity is the presentation of
the disease to the clinics in the late stages. Therefore, bio-
markers that could detect the disease early, predict aggres-
sive behavior, and/or define molecular markers for more
effective targeted therapy could offer newer insights to
improve the existing therapeutic window.
Expression profiling based on microarrays has been
used extensively in aiding cancer diagnosis, classifying
cancer subtypes, determining prognosis and predicting
response to therapy. The first report demonstrating clini-
cally relevant classification of cancer based on microarray
was from Golub et al. [4], where a 50-gene signature
could distinguish AML (acute myeloid leukemia) and
ALL (acute lymphoblastic leukemia) patients with 100%
accuracy. Again, using microarray Alizadeh and coworkers
identified new subtypes of diffuse large B-cell lymphoma
(DLBCL) that correlated with long-term (8–10 year)
patient survival [5]. In breast cancer, expression profiling
has helped in the identification of ER (estrogen-receptor)-
positive and ER-negative cancers as fundamentally distinct
diseases at the molecular level [6, 7] as well as shown that
prognosis of patients with ER-positive disease is largely
determined by the expression of proliferation-related
genes [8]. Based on the gene signatures identified from
gene expression studies two diagnostic chips have been
developed which are now used extensively to take clinical
decisions in breast cancer; the FDA-approved Mamma-
Print assay (Agendia, The Netherlands) and Oncotype DX
(Genomic Health, Redwood City, CA) [9, 10]. In prostate
cancer, a clinical test based on prostate cancer 3 (PCA3)
biomarker mRNA in urine, was recently approved in Eur-
ope under CE trademark [11].
In cervical cancer, expression profiling studies have
helped to identify a number of potential diagnostic mark-
ers like mini chromosome maintenance 5 (MCM5), cell
division cycle protein 6 (CDC6) and chromatin licensing
and DNA replication factor 1 (CDT1) [12, 13]. It has also
been used to understand the process of carcinogenesis
[14]; to probe for biomarkers of radiation response [15];
and to identify molecular signatures for predicting treat-
ment response [16, 17] and prognosis [18]. But few stud-
ies have been done to analyze the molecular changes
during the progression of cervical cancer from normal
cervix through International Federation of Gynaecology
and Obstetrics (FIGO) stages I to IV, based on which
treatment decisions are mostly made. This is especially
true in the case of Indian cohort of patients where,
notwithstanding the overwhelming burden of the disease
(1/4th of the global incidence), very few gene expression
studies are available [16, 19].
In this study we utilized gene expression profiling to
analyze changes in cervical cancer, during the progression
from FIGO stage I to III as compared to normal cervix.
We also analyzed the expression profiles of cervical cancer
samples based on the early or advanced stage of the dis-
ease. We have been able to identify a set of genes which
could serve as signatures for the progressive stages (FIGO
I, II, III) as well as few potential biomarkers that have
diagnostic or therapeutic significance. Also by the analysis
of expression profiles of cervical cancer at the early and
advanced stages we were able to identify potential bio-
markers that could serve as therapeutic targets for the
advanced stages. We then successfully validated these
potential biomarkers in the 29 samples used for micro-
array as well in an independent set of 34 samples.
Material and Methods
Clinical tissue specimens
Frozen cervical tumor biopsies used in the study were
obtained through Radiation Oncology Department and
Tumour Tissue Repository of the Tata Memorial Hospi-
tal, Mumbai, according to the Hospital’s Institutional
Review Board (IRB) guidelines. Noncancerous cervical tis-
sues were procured from patients who were undergoing
hysterectomy for reasons other than cervical cancer, from
D. Y. Patil Hospital and Research Centre, Navi Mumbai,
after obtaining IRB approval and written informed con-
sent from the patients. The samples were collected in
liquid nitrogen and a laboratory code was assigned to
maintain confidentiality.
For microarray analysis, cervical cancer samples (n = 25)
at FIGO stages I (n = 8), II (n = 9), and III (n = 8) and
four normal cervix tissues were included. The same samples
were used for identifying genes discriminating early (FIGO
stage IA, IB, and IIA, n = 11) and advanced stages of cervi-
cal cancer (FIGO stage IIB, IIIA, and IIIB, n = 14). In addi-
tion, an independent set of 34 samples comprising normal
cervix tissues (n = 12) and cervical tumor samples at FIGO
stages I (n = 3), II (n = 9), and III (n = 10) were used for
validating selected genes.
Processing of samples and RNA extraction
Tissue samples were first subjected to cryosectioning to
collect sections for hematoxylin and eosin (H&E) staining
as well as for the isolation of RNA. Microscopic examina-
tion of H&E-stained sections of tumor samples was
carried out by the pathologist (K. D.) to assess percentage
of tumor in the sample, while in nonmalignant cervical
samples the stained sections were analyzed to check for
any morphologic abnormalities. Normal cervical tissue
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was represented by normal stratified squamous epithelium
and underlying loose connective tissue stroma. Poorly
differentiated cervical squamous carcinoma had a sheeted
appearance with hardly any stroma visible (Fig. S1). Only
those samples with 50% or more tumor cells were consid-
ered for microarray studies and validation. Extraction of
total RNA from cervical tumor sections was done using
RNeasy mini kit (Qiagen, Hilden, Germany), while isola-
tion of RNA using TriZol reagent (Life Technologies,
Carlsbad, CA) followed by clean-up using RNeasy mini
kit was done for normal cervical tissues. The quality and
integrity of the RNA was checked by denaturing agarose
gel electrophoresis.
Expression profiling by microarray
Whole genome mRNA expression profiling of the cervical
samples was performed using Human Arrays 19K
(University Health Network Microarray Center, Ontario
Cancer Institute, Canada). Two-color microarray experi-
ment was carried out using cervical samples as target
(labeled with Cy5 fluorescent dye, GE Healthcare, Buck-
inghamshire, U.K.) and universal human reference RNA,
UHRR (Stratagene Corporation, La Jolla, CA) (labeled
with Cy3 fluorescent dye, GE Healthcare, Buckingham-
shire, U.K.) as reference. Labeling and hybridization were
done according to standard protocols. Scanning of the
arrays were done on GenePix Professional 4200A Scanner
(Axon Instruments, Inc., Molecular Devices, Sunnyvale
CA) using the GenePix Pro 5 software. The raw data in
.gpr format is available from GEO database (Accession ID
GSE46857).
Microarray data analysis
Preprocessing of the data
Analysis of the microarray data was carried out using
Agilent Genespring GX11.5 software. The raw data was
log2 transformed and normalized using Lowess normaliza-
tion. For individual analyses, only the probe sets with nor-
malized fluorescence intensity values between 100% and
20% of the whole data, present in at least 75% of the sam-
ple cohort were included. Additionally, only the probe sets
which were flagged as “Present” or “Marginal” in 100% of
the samples in each class were used for further analysis.
Gene selection, clustering, and pathway
analysis
In order to identify genes which were differentially
expressed between the normal (N) and different stages of
cervical cancer, a supervised method of analysis was
adopted. Probe sets with twofold or more difference in
average expression in at least one out of six pairs of
conditions (N vs. Stage I, N vs. Stage II, N vs. Stage III,
Stage II vs. Stage I, Stage III vs. Stage II, and Stage III vs.
Stage I) were selected for significance analysis by one-way
analysis of variance (ANOVA) at a P-value cutoff of 0.05
and using permutative method for P-value computation
(50,000 permutations). Benjamini and Hochberg false
discovery rate (FDR) was used for multiple testing correc-
tion [20]. The differentially expressed genes were clus-
tered using Hierarchical clustering analysis based on
Pearson correlation and average linkage rule.
In order to define genes differentially expressed
between the early and advanced stages of cervical cancer,
probe sets with twofold or more difference in average
expression between the two conditions were selected. The
selected genes were further subjected to unpaired T-test
with unequal variance (Welch t-test) at a P-value cutoff
of 0.05 using permutative method of P-value computation
(50,000 permutations).
To identify the biological interactions between the
differentially expressed genes and to identify the pathways
that differed most between conditions analyzed, the gene
sets identified to be differentially expressed were subjected
to pathway analysis using KEGG pathway analysis soft-
ware and Biointerpreter software (Genotypic technology,
Bangalore, India).
Quantitative real-time PCR
Reverse transcription reactions were performed using
standard protocols with SuperscriptTM first strand synthe-
sis kit (Invitrogen, Carlsbad, CA). SYBR green (Invitro-
gen, Carlsbad, CA) based chemistry was utilized for
quantitative real-time polymerase chain reaction (qRT-
PCR) reactions. All PCR reactions were performed in
duplicate and run on ABI Prism 7900 Sequence Detection
System (Life Technologies, Carlsbad, CA). Each sample
was normalized based on the average expression of four
housekeeping genes (18S rRNA, RPS18, TBP, and HMBS).
The comparative CT (ΔCT) method was used for quanti-
fication of gene expression and relative quantity of the
gene of interest was calculated as 2DCT. Primer sequences
used in the study are listed in Table S1.
Statistical analysis of the real-time data was performed
on GraphPad Prism software (GraphPad Software Inc.,
San Diego, CA). Depending on whether data followed
normal distribution or not Welch t-test or Mann–
Whitney U test was used for significance testing. A P-
value of <0.05 was considered significant. Pearson (linear)
correlation analysis between the microarray data and real-
time data was also performed. A two-sided P ≤ 0.01 and
a correlation coefficient of 0.7 were considered significant.
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Results
Whole genome expression profiling of
progressive stages in cervical cancer
Here, expression of 19,200 human genes and expressed
sequence tags were compared to identify genes differen-
tially expressed between normal cervix and cervical cancer
samples at different progressive FIGO stages (I–III). Sig-
nificance analysis using one-way ANOVA corrected with
Benjamini and Hochberg FDR at P ≤ 0.05 and a fold
change cutoff of 2 identified 1377 genes to be differen-
tially expressed. Interestingly, overall, there was >80%
overlap in the gene panels differentially expressed between
normal and successive FIGO stages (1161, 1224, and 1163
genes, respectively, in N vs. Stage I, N vs. Stage II, and N
vs. Stage III) (Fig. S2). Thus, though there was evident
deregulation of genes in invasive cancer as compared to
normal, not much increase in the number of genes dereg-
ulated or significant change in the expression of deregu-
lated genes with progression of the disease could be seen
(Fig. S3).
In order to identify specific genes deregulated in the
initial and later stages of cervical cancer progression,
genes differentially expressed compared to normal only in
the early stages I and II (n = 69) or in late stages II and
III (n = 56) were examined further. Surprisingly, while
individual genes deregulated in the two groups were
different, they shared similar functional categories. For
instance, both the groups displayed major downregulation
of genes involved in cell matrix interaction (ADAM33),
adhesion (CALD1, CELSR2), tight junctions (PARD3B),
and phosphatases (PPP2R2C). Additionally, while genes
involved in metabolic pathways (AGA, BAAT, AGXT2),
RNA splicing (PRPF4B) and proteosomal (PSMD8) and
ribosomal proteins (RPS6KA1) were upregulated in Stage
I and II, genes related to chromatin remodeling (PATZ1),
cell division (DONSON, NASP), and kinases (SRPK1)
were up in Stage II and III.
Distinct gene expression signatures defining
pathological stages
To identify gene signatures which could distinguish the
progressive FIGO stages, genes (n = 201) which were
deregulated exclusively in Stages I, II, and III (compared to
normal) were selected. By using hierarchical clustering
based on Pearson correlation and average linkage on these
selected genes we were able to delineate the different stages
and the normal samples into four definite clusters (Fig. 1).
A fifth cluster comprised of a few misclassified samples
(three Stage I, one Stage II, and one Stage III). Distinct gene
clusters indicating up and downregulated genes in hierarchi-
cal cluster were evaluated for their molecular function.
These analyses revealed that in Stage I, genes involved in
DNA repair and replication (RPA3), angiogenesis (VAV2),
and ERBB signaling (NRG3) were upregulated, while genes
involved in cytoskeletal remodeling (DPYSL3), transcription
factor (TCF4) and tumor suppressor genes (SASH1) were
downregulated. Samples in Stage II were marked by upregu-
lation of DNA repair genes (HYRC) and genes with func-
tions which may lead to extensive proliferation like the
kinases (NEK2), growth factors (PGF), and genes with mito-
genic effect (FGL1), while in Stage III, cell cycle regulatory
genes (RCC1), certain genes related to metastasis (LAMA5)
and oncogenes (MECOM) were overexpressed. Genes
highly downregulated in the advanced stages included,
tumor suppressors (NAV3), phosphatases (PTPRS,
DUSP1), and cytoskeletal proteins (PKP3). Thus overall,
angiogenesis and proliferation-related genes were overex-
pressed in the early stages while genes related to metastasis
were the ones overexpressed as the cancer progresses.
FIGO Stage
I
II
III
N
Colour range
–2 0 2
Figure 1. Clustering and TreeView analysis using International
Federation of Gynaecology and Obstetrics (FIGO) stage gene
signatures. Hierarchical clustering using 201 genes classified the
samples based on FIGO stages. The gene clusters in green boxes
represents genes over/under-expressed in specific stages.
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Differential expression of genes
independent of cancer stages
Comparison of genes differentially expressed in progres-
sive FIGO stages identified 1015 genes common among
the three groups, indicating that these genes were
deregulated throughout cervical carcinoma progression.
Two-way cluster and TreeView analysis based on the
expression of these 1015 genes by self-organizing maps
(SOM) utilizing Euclidean distance metric could distinctly
separate the normal and cancer samples (Fig. S4). Inter-
estingly, comparison of this gene set (668 annotated genes
from 1015) with the published literature [14, 21–25]
showed considerable overlap (Table S2). The study also
identified novel genes of significance; for instance, the
DNA repair gene-BRCA1 expression was found to be
upregulated in cervical cancer as compared to normal
cervix in this study.
Altogether, almost 50% of the genes differentially
expressed in cervical cancer as compared to normal cervix
were upregulated. Pathway analysis of differentially
expressed genes showed metabolic pathways, pathways in
cancer and signaling pathways to be significantly upregu-
lated, while focal adhesion, cytokine–cytokine receptor
interaction, WNT signaling, etc., were significantly down-
regulated in cancer compared to normal cervix (Fig. 2).
Genes differentially expressed in advanced
versus early stages of cervical cancer
FIGO stages IA to IIA were considered “early,” while pro-
gressive stages IIB onward were considered “advanced” as
described before [25, 26]. Statistical significance analysis,
by unpaired Welch t-test using permutative method of P-
value computation identified 161 genes to be significantly
differentially expressed between the groups, at a fold
change cutoff of ≥2. Twenty-nine genes were differentially
expressed between early and advanced stage of cervical
cancer on a stringent analysis at a P-value cutoff of 0.01
and fold change cutoff of 2.
As the number of annotated genes in this selected gene
list was less, pathway analysis could not identify any of
the major pathways as clearly up/downregulated. Analysis
of function of the annotated genes in the 161-gene panel,
however, indicated that apoptosis-related genes (BNIP3,
BCL2L11, TNFSF13, PERP, ATF6, BPTF) and phosphata-
ses (DUSP1, PPP2R5E, PTPN4) were underexpressed
whereas genes involved in transcriptional activation
(ATF2, GTF3C1, TFE3, MCRS1) and signaling, and
migration of cells (MAPRE3, PAK7, PIK3R1) were over-
expressed in advanced stage as compared to early-stage
cervical cancer.
Two-way hierarchical clustering (Pearson correlation
and average linkage rule) using the 29 genes (P ≤ 0.01
and fold change [FC] = 2) gave two major clusters, one
comprising of all of the early-stage samples and second,
with most advanced-stage samples (Fig. 3). One of the
samples in the advanced stage clustered along with the
early-stage samples and two advanced-stage samples clus-
tered separately, and closer to early-stage cluster.
Real-time RT-PCR (qRT-PCR) evaluation of
selected candidate genes in microarray as
well as independent samples
To confirm differential expression of the genes identified
by microarray, a few selected genes were validated by
qRT-PCR. From the genes differentially expressed
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Figure 2. Significantly altered pathways in cervical cancer. The analysis was done using Biointerpreter software. (A) Pathways upregulated.
(B) Pathways downregulated.
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between normal tissue and cervical cancer (1015) we
selected nine genes (BRCA1, SPP1, PRKAR1B, LAMA2,
PCNA, STK17A, VAV2, DUSP1, and APP), which had
either been reported in other cancers or were potential
biomarkers as they were secretory proteins. Among these,
LAMA2, DUSP1, PRKAR1B, and APP were downregulated
while the rest of the genes were upregulated in cancer as
compared to normal cervical samples in the samples used
for microarray. Remarkably, seven out of these nine genes
showed significant (P ≤ 0.05) difference in expression
between the compared groups (Normal vs. cancer, Nor-
mal vs. Stage I, Normal vs. Stage II, and Normal vs. Stage
III) as determined by microarrays (Fig. 4). To evaluate
the degree of correlation between qRT-PCR and micro-
array data a linear correlation analysis (Pearson) was
performed. The analysis revealed significant correlation
between the results from the two analysis (P ≤ 0.01)
(Fig. 5).
Expression of the seven validated genes (BRCA1, SPP1,
LAMA2, PCNA, STK17A, VAV2, DUSP1) was further
analyzed in an independent cohort of 34 cervical samples
(12 normal, 3 Stage I, 9 Stage II, and 10 Stage III) by
qRT-PCR. Statistically significant differential expression of
the genes was observed in this independent sample set as
well, further confirming the findings of our microarray
analysis (Fig. 4).
From the genes differentially expressed between early
and advanced stages of cervical cancer, six genes – three
upregulated (BCL3, IGF2, and PIK3R1) and three down-
regulated (PTPN4, PERP, and DUSP1) were selected for
validation by qRT-PCR. Of these, PIK3R1 and DUSP1
were found to be significantly differentially expressed in
the samples used for microarray (Fig. 6).
Discussion
Cervical carcinoma is curable in majority of cases if diag-
nosed early. Routine clinical management of the disease
relies on the clinical stage and histological classification as
described by FIGO. Though the treatment modality
followed is essentially effective in the early stages, with a
high 5-year survival rate of >90%, the rate decreases con-
siderably in the later stages to as low as 16.4% in Stage
IVA, whereas palliative treatment is the only option avail-
able for most advanced Stage IVB and few Stage IVA
cancers. Thus, even though histological staging provides
valuable information about the clinical behavior of the
tumor, it has limited predictive value. Distant metastasis
could be observed even in patients with small-volume
tumors. Furthermore, the histological appearance of the
tumors could not fully reveal the underlying complex
genetic alterations and the biologic events involved in
their development and progression. Although various
clinical predictive and prognostic factors and treatment
outcome have been established, molecular events which
could predict outcome and divergent behavior need to be
investigated further.
In this study, we have attempted to investigate the
alterations in the gene expression profile of cervix uteri,
as it progresses through various FIGO stages of carci-
noma, in a cohort of Indian patients. Expression profiles
of cervical cancer samples (n = 25) at different progres-
sive FIGO stages (I–III) were compared with normal
cervix (n = 4). Analysis of the genes differentially
expressed between normal cervix and stages of cervical
cancer indicated that majority of the genes were deregu-
lated even at the earliest stage of invasive cancer. In fact,
there were >80% overlap (1015 of total 1377) in the panel
Stage
Advanced
Early
Colour range
–2 0 2
Figure 3. Hierarchical clustering and TreeView analysis of genes
differentially expressed in advanced- versus early-stage cervical cancer.
Twenty-nine differentially expressed genes at P ≤ 0.01 and FC 2 was
used for the analysis.
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of genes differentially expressed between normal cervix
and progressive FIGO stages, indicating that the deregula-
tion of these genes occur early and stays throughout cer-
vical carcinoma progression. An increase in the number
of deregulated genes, as well as increase in expression of
individual genes with progressive preneoplastic conditions
(CIN1, 2, and 3) leading to invasive cancer have been
reported earlier [27, 28]. Evaluation of the genes exclu-
sively deregulated either in the initial (Stage I and II) or
later stages (Stage II and III) of cervical cancer progres-
sion showed that while individual, deregulated genes were
different in the two cases, they shared similar functional
category. For instance, genes related to cell matrix interac-
tion, adhesion, cytoskeletal reorganization and phosphatases
were downregulated while metabolic genes and genes
related to cell division and proliferation were upregulated
in both the gene panels.
The analysis also revealed few genes differentially
expressed uniquely in the different stages. An unsuper-
vised hierarchical clustering using these selected genes
(n = 201) could separate the different stages and the nor-
mal samples into four definite clusters (Fig. 1), though
there were a few misclassifications.
Majority of the genes identified to be differentially
expressed were altered in cervical cancer as opposed to
normal cervix, irrespective of the FIGO stages. A com-
parison of these genes (668 annotated of 1015) to previ-
ous reports showed a considerable overlap (126 genes)
with the six published studies (Table S2) [14, 21–25].
Among these, 96 genes were in common with data pub-
lished by Perez-Plasencia et al. [23] where expression
profiles of three normal cervical samples were compared
to eight FIGO stage II cervical cancer samples. Wong
et al. [25] compared gene expression profiles between 29
cervical cancers and 18 normal cervical tissues and iden-
tified 102 genes to be differentially expressed between the
comparing groups. Eleven genes reported in their study
were in common to the panel of genes identified in this
study. Also 11 genes identified in this study were
reported to be differentially expressed in three or more
of the compared reports. These included some important
genes like DNA replication licensing protein MCM2,
which is tested as biomarker for screening of cervical
lesions [29]; CENPF which plays a role in chromosome
segregation during mitosis and is reported to be fre-
quently amplified in hepatocellular carcinoma [30]; PRC1
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which is involved in cytokinesis [31]; and CRYAB a
tumor suppressor [32].
Pathway analysis of annotated genes using Biointerpret-
er software showed metabolic pathways, pathways in
cancer and signaling pathways to be significantly upregu-
lated, while focal adhesion, cytokine–cytokine receptor
interaction and WNT signaling were significantly down-
regulated in cervical carcinoma (Fig. 2).
Even as an overlap of genes differentially expressed
between normal cervix and cervical cancer was observed
among our data and published literature, majority of the
genes identified is reported for the first time in cervical
cancer. For instance, in the study upregulation of DNA
repair gene – BRCA1 was observed in cancer as compared
to normal cervix. Validation of the gene using real-time
PCR showed a 9.2-fold increase in BRCA1 expression in
cervical cancer as compared to normal cervix. Over
expression of BRCA1 has been demonstrated in lung can-
cer and sporadic ovarian cancer where it was reported to
lead to chemoresistance [33, 34]. However, to the best of
our knowledge increased expression of the gene in cervi-
cal cancer has not been reported.
We could also identify other genes of diagnostic or
therapeutic significance in the study. One such gene
is SPP1 (secreted phosphoprotein 1 also known as
osteopontin [OPN]) that encodes an extracellular glycosy-
lated bone phosphoprotein. Real-time validation study
showed the gene to be overexpressed by 34.6-fold in
cervical cancer. In a meta-analysis carried out to evaluate
OPN as a marker for aggressiveness and patient survival,
Weber et al. [35] concluded that OPN was significantly
associated with survival in several cancers. OPN has been
associated with poor prognosis in head and neck cancer
patients [36] and implicated to predict recurrence in oral
squamous cell carcinoma [37]. Increased serum concen-
trations of OPN have been reported in AML, chronic
myelogenous leukemia and multiple myeloma [38].
Upregulation of SPP1 has been reported in expression
profiling studies of cervical cancer as well [25, 39]. Clini-
cal significance of elevated OPN in plasma of cervical
cancer patients as a diagnostic and prognostic biomarker
was evaluated in a study by Cho et al. [40]. Plasma OPN
levels were measured in 81 patients with cervical cancer,
34 patients with carcinoma in situ (CIS) of the uterine
cervix, and 283 healthy women using enzyme-linked
immunosorbent assay (ELISA). As a diagnostic marker
for cervical cancer, OPN had a sensitivity and specificity
of 50.6% and 95.0%, respectively. SPP1 expression also
correlated significantly with overall survival (P = 0.002)
and disease-free survival (P = 0.033) [40].
Another gene of importance validated was PCNA
(proliferating cell nuclear antigen), which increases the
processivity of leading strand synthesis during DNA rep-
lication and is involved in the RAD6-dependent DNA
repair pathway [41]. Astudillo et al. [42] noted a signifi-
cant increase in protein expression of PCNA with
increasing grades of cervical lesions from normal epithe-
lia to invasive squamous cell carcinoma. The E7 onco-
protein of high-risk HPV is known to activate PCNA
possibly by abrogation of normal cell cycle control by
the E7 oncogene, reverting the p21 (Cip1)-mediated
inhibition of PCNA [43], hence the increase in the level
of PCNA with progression of the disease. Increased
PCNA expression was also shown to be related to a
shorter disease-free period and overall survival time in
patients with breast cancer [44]. The use of PCNA along
with Ki-67 has been suggested as specific proliferative
markers of prostate cancer for early cancer diagnosis
[45].
DUSP1/MKP1 is a dual specificity phosphatase of MAP
kinase pathway that may play an important role in the
negative regulation of cellular proliferation. DUSP1 was
downregulated in cervical cancer samples in this study
which concurs with published reports [23]. In fact, a
progressive reduction in the expression of DUSP1 was
observed as the disease progressed from normal through
FIGO stages I–III. Gradual decrease in the expression of
the gene has been shown in lung cancer as the tissue type
went from normal to increasingly undifferentiated carci-
noma [46]. Conversely, a role of DUSP1 in angiogenesis,
invasion and metastasis in non-small-cell lung cancer
(NSCLC) cells has also been demonstrated by Moncho-
Amor et al. [47] by downregulation of DUSP1 in H460
cell line. There is a balance between the activation and
inactivation of the mitogen-activated protein kinases
which is mediated by DUSPs which modulates prolifera-
tion or apoptosis in different tissues. In order to under-
stand its role in cervical cancer progression, further
studies need to be carried out.
Two genes (VAV2 and STK17A) from the 201-gene
panel were selected for validation by qRT-PCR. VAV2
works as a guanosine nucleotide exchange factor (GEF)
that activates different members of the Rho/Rac family of
GTPases in a tyrosine phosphorylation-dependent manner
[48]. Recent reports provide evidence for its critical role
in host-mediated tumor progression and angiogenesis,
particularly in tumor endothelium [49]. STK17A is a
serine/threonine kinase which is known to have apopto-
sis-inducing activity [50]. It is reported to be downregu-
lated in many cancers and homozygous deletions are
noted in melanoma cell line (etoposide-resistant) and lar-
yngeal squamous cell carcinoma cell line [51]. Interest-
ingly overexpression of STK17A has been reported in
other cancers like glioblastoma where it has been impli-
cated to correlate to poor prognosis in those patients
[52]. In this study, VAV2 was specifically overexpressed
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in Stage I in the microarray data while STK17A was spe-
cifically overexpressed in Stage II. However, on real-time
validation these genes were found to be overexpressed in
other FIGO stages as well.
The 19K microarray data of the three FIGO stages I, II,
and III (n = 25) were further divided into early stage (IA,
IB, IIA) (n = 11) and advanced stage (IIB, IIIB) (n = 14)
with the aim to identify biomarkers and therapeutic
targets for the advanced stages. There are only very few
studies available comparing early and advanced-stage cer-
vical cancer. In one such study, Wong et al. [25] could
identify only two genes CTGF and RGS1 differentially
P VALUE > 0.0001 P VALUE > 0.0001
P VALUE > 0.0001 P VALUE > 0.018
Pearson r = 0.74
Pearson r = 0.43Pearson r = 0.68
Pearson r = 0.78
BA
DC
Figure 5. Pearson correlation analysis of microarray and real-time polymerase chain reaction (PCR) data. Microarray fluorescent intensity is given
on the x-axis and threshold cycle value from real-time PCR data are given on y-axis. A: PCNA; B: DUSP1; C: STK17A; D: SPP1.
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Figure 6. Box plots depicting validation of differentially expressed genes by real-time PCR. DUSP1 was downregulated while PIK3R1 was
upregulated in advanced-stage cervical cancer. E, early stage (n = 11); A, advanced stage (n = 14); PCR, polymerase chain reaction.
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expressed between the groups. Neither of these genes was
found to be differentially expressed in our data. RGS1
was not represented in the 19K chip we used for the
study and the difference in expression of CTGF between
the two groups was not significant in our cohort of
patients.
Analysis of function of the annotated genes in the 161-
gene panel indicated that apoptosis-related genes (BNIP3,
BCL2L11, TNFSF13, PERP, ATF6, BPTF) and phosphata-
ses (DUSP1, PPP2R5E, PTPN4) were underexpressed
whereas genes involved in transcriptional activation
(ATF2, GTF3C1, TFE3, MCRS1) and signaling, and
migration of cells (MAPRE3, PAK7, PIK3R1) were overex-
pressed in advanced stage as compared to early-stage
cervical cancer.
Many of the genes which were overexpressed in
advanced stages are known to play critical roles in
tumor progression, metastasis as well as inducing treat-
ment resistance in many cancers. For instance, ATF2
(activating transcription factor 2) a basic transcription
factor has been reported to be a regulator of radiation
and drug resistance in melanomas [53] and known to
induce epithelial–mesenchymal transition (EMT) in pan-
creatic cancer cell lines [54]. Tumor-targeted ATF2
modulators may be useful as sensitizers in the treat-
ment of ATF2-overexpressing tumors [53]. PIK3R1, a
regulatory subunit of phosphatidylinositol 3-kinase has
been implicated in tumorigenesis and metastasis in vari-
ous cancers. Overexpression of this gene has been associated
with advanced stage and poor survival in non-small-cell
lung cancer [55]. PIK3R1 has been suggested as a potential
therapeutic target in several cancers including glioblastoma
multiforme and NSCLC [55, 56]. Targeting the gene via
adeno/lentivirus-mediated shRNA has shown promising
results in many preclinical studies [56, 57]. In our micro-
array data, the gene was overexpressed in advanced stages
and was validated by real-time PCR. Another observation
was decreased expression of DUSP1 – a phosphatase gene in
cervical cancer samples when compared to normal cervix.
Underexpression of the gene in advanced stages as compared
to early stages could demonstrate a progressive downregula-
tion of this phosphatase with advancement of cervical can-
cer, suggesting that it may be playing a very critical role in
cervical cancer progression. The gene was validated by real-
time PCR as well.
Overall, in this study we were able to identify a panel
of genes that could distinguish cervical cancer from nor-
mal cervix, which included many genes of therapeutic
and diagnostic significance. Of particular note is the over
expression of the gene SPP1, which could potentially
serve as serum diagnostic marker for cervical cancer. Also,
PIK3R1 a gene overexpressed in advanced stages has been
suggested as a potential therapeutic target in several can-
cers. We were able to identify a set of genes that could
serve as gene signatures for progressive stages (FIGO I, II,
III) of cervical cancer, though studies including larger
sample sets need to be undertaken.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. H&E-stained sections of uterine cervical tissue.
The panel A represents tissue sections of normal cervix
while cervical tumor sections are portrayed in panel B.
Normal cervical tissue was represented by normal strati-
fied squamous epithelium and underlying loose connec-
tive tissue stroma. Poorly differentiated cervical squamous
carcinoma had a sheeted appearance with hardly any
stroma visible.
Figure S2. Percent overlap between total differentially
expressed genes and genes differentially expressed in Stage
I, II, and III.
Figure S3. Profile plot of expression of 1015 genes across
progressive cervical cancer stages as compared to normal.
Gene expression did not vary greatly among different can-
cer stages though there was evident deregulation in tran-
scription as the status changed from normal to cancer. N,
normal cervix; I, FIGO stage I; II, FIGO stage II; III,
FIGO stage III.
Figure S4. Clustering and TreeView analysis of genes dif-
ferentially expressed in cervical cancer. Clustering using
self-organizing map (SOM) of 1015 genes distinctly clus-
tered normal cervical samples together and away from
invasive cancer samples.
Table S1. List of primers used in the study.
Table S2. Overlap of genes differentially expressed
between healthy cervical tissue and cervical cancer in the
literature.
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